Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $36.00

Kymera Therapeutics (NASDAQ:KYMR) had its price objective upped by B. Riley from $31.00 to $36.00 in a research note published on Tuesday, Benzinga reports. They currently have a neutral rating on the stock. B. Riley also issued estimates for Kymera Therapeutics’ FY2028 earnings at ($4.48) EPS.

Several other research analysts also recently commented on the stock. HC Wainwright reiterated a buy rating and issued a $46.00 target price on shares of Kymera Therapeutics in a report on Monday, June 17th. Oppenheimer dropped their price objective on shares of Kymera Therapeutics from $53.00 to $52.00 and set an outperform rating on the stock in a report on Friday, May 3rd. Seven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus target price of $42.09.

Kymera Therapeutics Trading Up 7.6 %

KYMR stock opened at $39.00 on Tuesday. The firm has a market cap of $2.39 billion, a PE ratio of -15.54 and a beta of 2.22. Kymera Therapeutics has a 1 year low of $9.60 and a 1 year high of $45.31. The company has a fifty day simple moving average of $33.84 and a 200 day simple moving average of $34.66.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, May 2nd. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. The firm had revenue of $10.30 million for the quarter, compared to the consensus estimate of $14.24 million. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The business’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.70) EPS. As a group, analysts forecast that Kymera Therapeutics will post -2.86 EPS for the current fiscal year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of the business’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total value of $17,345,811.60. Following the transaction, the director now directly owns 723,246 shares in the company, valued at $27,635,229.66. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of the business’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total value of $17,345,811.60. Following the transaction, the director now directly owns 723,246 shares in the company, valued at $27,635,229.66. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Joanna Horobin sold 8,500 shares of the business’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The disclosure for this sale can be found here. Insiders have sold a total of 479,200 shares of company stock valued at $18,219,660 over the last quarter. 15.82% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Large investors have recently modified their holdings of the stock. Quest Partners LLC acquired a new position in shares of Kymera Therapeutics during the fourth quarter worth approximately $78,000. Comerica Bank lifted its position in shares of Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after purchasing an additional 400 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Kymera Therapeutics by 352.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock worth $164,000 after purchasing an additional 5,002 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after purchasing an additional 295 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its position in shares of Kymera Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 7,359 shares of the company’s stock worth $187,000 after purchasing an additional 1,866 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.